Compare Automatic Data Processing Inc (ADP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs TG Therapeutics Inc — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $107.69B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Automatic Data Processing Inc is far larger — about 14.1× TG Therapeutics Inc's market cap, and Automatic Data Processing Inc pays a 2.51% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADP | TGTX | |
|---|---|---|
Market Cap | $107.69B | $7.64B |
Sector | Industrials | Health |
52-Week High | $309.03 | $59.06 |
52-Week Low | $188.79 | $26.94 |
Enterprise Value | $108.73B | $7.84B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $269.14, down 1.66% on the day, with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings, beating estimates with EPS of $2.62 versus $2.57 expected, and revenue growth continues steadily. Analyst consensus is a $280.50 price target, though the majority rating is Hold. Recent news highlights dividend declarations and employment data reports.
Outlook remains positive due to consistent earnings beats and margin expansion, but high valuation multiples like a P/E of 24.78 pose a risk if growth slows. Key risks include economic sensitivity affecting payroll services demand and competitive pressures in HR solutions.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
